

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA

IN RE MANNKIND	)	Lead Case No. 11-cv-05003-GAF-
CORPORATION DERIVATIVE	)	SSx
LITIGATION	)	(Derivative Action)
This Document Relates To:		)
ALL ACTIONS	)	NOTICE OF PENDENCY AND
	)	PROPOSED SETTLEMENT OF
	)	SHAREHOLDER DERIVATIVE
	)	ACTION
	)	Judge: Gary A. Feess
	)	Dept.: 740
	)	Date Action Filed: August 12, 2011

1 **TO: ALL CURRENT OWNERS OF MANNKIND CORPORATION**  
2 **(“MANNKIND” OR THE “COMPANY”) COMMON STOCK**

3 **THIS NOTICE RELATES TO THE PENDENCY AND PROPOSED**  
4 **SETTLEMENT OF SHAREHOLDER DERIVATIVE LITIGATION.**  
5 **PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF**  
6 **YOU ARE A MANNKIND SHAREHOLDER, THIS NOTICE CONTAINS**  
7 **IMPORTANT INFORMATION ABOUT YOUR RIGHTS.**

8 **YOU ARE HEREBY NOTIFIED**, pursuant to an Order of the U.S. District  
9 Court for the Central District of California (the “Court”), a proposed settlement has  
10 been reached by the parties to the following shareholder derivative actions brought  
11 on behalf of MannKind: (i) *In re MannKind Corporation Derivative Litigation*,  
12 Lead Case No. 11-cv-05003-GAF-SSx , pending in the U.S. District Court for the  
13 Central District of California (“Federal Derivative Action”); and (ii) *In re*  
14 *MannKind Corporation Derivative Shareholder Litigation*, Lead Case No.  
15 BC454931, pending in the Superior Court of the State of California, County of Los  
16 Angeles (“State Derivative Action”) (collectively, the “Actions”).

17 As explained below, the Court will hold a Settlement Hearing on November  
18 19, 2012 at 9:30 a.m., before the Honorable Gary A. Feess, at the Edward R.  
19 Roybal Federal Building and United States Courthouse, 255 East Temple Street,  
20 Los Angeles, CA 90012, to determine whether to approve the Settlement. You  
21 have an opportunity to be heard at this hearing.

22 The terms of the settlement are set forth in the parties’ Stipulation of  
23 Settlement dated August 3, 2012 (the “Stipulation”) and summarized in this notice.  
24 If approved by the Court, the Settlement will fully resolve the Actions, including  
25 the dismissal of the Actions with prejudice. For a more detailed statement of the  
26 matters involved in the Actions, the Settlement, and the terms discussed in this  
27 notice, the Stipulation may be inspected at the Clerk of Court’s office, 255 East  
28 Temple Street, Los Angeles, CA 90012. The Stipulation is also available for  
viewing on the website of MannKind (<http://www.investors.mannkindcorp.com>),

1 as well as the websites of Johnson Weaver, LLP  
2 (<http://www.johnsonandweaver.com>), Robbins Umeda LLP  
3 (<http://www.robbinsumeda.com/notices.html>), and the Grant Law Firm, PLLC  
4 (<http://Grantfirm.com>).

5 This notice is not intended to be an expression of any opinion by the Court  
6 with respect to the merits of the claims made in the Actions, but is merely to advise  
7 you of the pendency and settlement of the Actions.

8 **There Is No Claims Procedure.** This case was brought to protect the  
9 interests of MannKind and its shareholders. The Settlement will result in changes to  
10 the Company's corporate governance, not in payment to individuals, and  
11 accordingly, there will be no claims procedure.

12 **I. DEFINITIONS USED IN THIS NOTICE**

13 As used in this Notice, the following terms have the meanings specified  
14 below:

- 15 1. "Actions" means, collectively, the Federal Action and the State  
16 Action.
- 17 2. "Court" means the U.S. District Court for the Central District of  
18 California.
- 19 3. "Current MannKind Shareholders" means any Person who owned  
20 MannKind common stock as of the date of the execution of the Stipulation and  
21 who continue to hold their MannKind common stock as of the date of Settlement  
22 Hearing, excluding the Individual Defendants, the officers and directors of  
23 MannKind, members of their immediate families, and their legal representatives,  
24 heirs, successors, or assigns, and any entity in which Individual Defendants have or  
25 had a controlling interest.

1           4.     “Defendants” means, collectively, nominal defendant MannKind,  
2 Alfred E. Mann, Hakan S. Edstrom, Matthew J. Pfeffer, Peter C. Richardson,  
3 Ronald Consiglio, Henry L. Nordhoff, David H. MacCallum, Michael Friedman,  
4 Kent Kresa, Barry E. Cohen, Diane M. Palumbo, and James S. Shannon.

5           5.     “Defendants’ Counsel” means Cooley LLP.

6           6.     “Effective Date” means the date by which the events and conditions  
7 specified in paragraph 6.1 of the Stipulation have been met and have occurred.

8           7.     “Federal Action” means the derivative actions that were consolidated  
9 and styled as *In re MannKind Corporation Derivative Litigation*, Lead Case No.  
10 11-cv-05003-GAF-SSx (C.D. Cal.).

11          8.     “Federal Plaintiff” means Donald Talley.

12          9.     “Federal Plaintiff’s Counsel” means Johnson & Weaver, LLP.

13          10.    “Final” means the date upon which the last of the following shall  
14 occur with respect to the Judgment approving the Stipulation, substantially in the  
15 form of Exhibit D attached hereto: (1) the expiration of the time to file a notice of  
16 appeal from the Judgment; or (2) if an appeal has been filed, the court of appeals  
17 has either affirmed the Judgment or dismissed that appeal and the time for any  
18 reconsideration or further appellate review has passed; or (3) if a higher court has  
19 granted further appellate review, that court has either affirmed the underlying  
20 Judgment or affirmed the court of appeal’s decision affirming the Judgment or  
21 dismissing the appeal. For purposes of this paragraph, an “appeal” shall not  
22 include any appeal that concerns only the issue of attorneys’ fees and expenses or  
23 the payment of an incentive award. Any proceeding or order, or any appeal or  
24 petition for a writ of certiorari pertaining solely to the application for attorneys’  
25 fees, costs, or expenses, shall not in any way delay or preclude the Judgment from  
26 becoming Final.

1           11. “Individual Defendants” means Alfred E. Mann, Hakan S. Edstrom,  
2 Matthew J. Pfeffer, Peter C. Richardson, Ronald Consiglio, Henry L. Nordhoff,  
3 David H. MacCallum, Michael Friedman, Kent Kresa, Barry E. Cohen, Diane M.  
4 Palumbo, and James S. Shannon.

5           12. “Judgment” means the Order and Final Judgment to be rendered by  
6 the Court, substantially in the form attached to the Stipulation as Exhibit D.

7           13. “MannKind” or the “Company” means nominal defendant MannKind  
8 Corporation, a Delaware corporation, and its affiliates, subsidiaries, predecessors,  
9 successors, and assigns.

10          14. “Notice” means this Notice of Proposed Settlement and of Settlement  
11 Hearing, a copy of which is also attached to the Stipulation as Exhibit C.

12          15. “Person” means an individual, corporation, limited liability  
13 corporation, professional corporation, partnership, limited partnership, limited  
14 liability partnership, association, joint stock company, estate, legal representative,  
15 trust, unincorporated association, government or any political subdivision or  
16 agency thereof and any business or legal entity and their spouses, heirs,  
17 predecessors, successors, representatives, or assignees.

18          16. “Plaintiffs” means collectively, Federal Plaintiff and the State  
19 Plaintiffs.

20          17. “Plaintiffs’ Counsel” means, collectively, any counsel who has  
21 appeared at any time for any of the Plaintiffs in the Federal Action and/or the State  
22 Action.

23          18. “Related Persons” means each of the Defendants and their past or  
24 present agents, officers, directors, attorneys, accountants, auditors, advisors,  
25 insurers, co-insurers, reinsurers, spouses, immediate family members, heirs,  
26 executors, personal representatives, estates, administrators, trusts, predecessors,  
27  
28

1 successors, and assigns or other individual or entity in which any Defendant has a  
2 controlling interest, and each and all of their respective past and present officers,  
3 directors, employees, agents, affiliates, parents, subsidiaries, divisions, attorneys,  
4 accountants, auditors, advisors, insurers, co-insurers, re-insurers, heirs, executors,  
5 personal representatives, estates, administrators, trusts, predecessors, successors,  
6 and assigns.

7 19. “Released Claims” means any and all actions, suits, claims, debts,  
8 demands, rights, liabilities, and causes of action of every nature, including both  
9 known and Unknown Claims (as defined in paragraph 30 below), existing directly  
10 or derivatively on behalf of MannKind, by Plaintiffs or any other shareholder of  
11 MannKind that arise out of or relate to: (i) the allegations asserted in the Actions;  
12 or (ii) the Settlement, except for any claims to enforce the Settlement. The Parties  
13 recognize that the FDA may take further negative or otherwise adverse actions  
14 regarding MannKind’s NDA for AFREZZA based on the same data and results  
15 giving rise to the Actions, and the “Released Claims” shall include any such  
16 actions, suits, claims, demands, rights, liabilities, or causes of action that arise out  
17 of or relate to any such later action by the FDA to the extent such action arises out  
18 of or relates to the same claims or issues raised in the Actions. Excluded from the  
19 term “Released Claims” are all claims alleged in the Securities Class Action.

20 20. “Released Persons” means collectively, MannKind and each of the  
21 Individual Defendants. “Released Person” means, individually, any of the  
22 Released Persons.

23 21. “Releasing Parties” means Plaintiffs (both individually and  
24 derivatively on behalf of MannKind), any other MannKind shareholder on behalf  
25 of MannKind and Plaintiffs’ Counsel. “Releasing Party” means, individually, any  
26 of the Releasing Parties.

27  
28

1           22. “Securities Class Action” means the securities fraud class actions that  
2 were consolidated and styled as *In re MannKind Corp. Securities Litigation*, Lead  
3 Case No. 11-cv-00929-GAF(SSx) (C.D. Cal.).

4           23. “Settlement” means the settlement and compromise of the Federal  
5 Action and the State Action as provided for herein.

6           24. “Settlement Hearing” means the hearing or hearings at which the  
7 Court will review the adequacy, fairness, and reasonableness of the Settlement.

8           25. “Settling Parties” means, collectively, each and all of the Plaintiffs (on  
9 behalf of themselves and derivatively on behalf of MannKind) and Defendants.  
10 “Settling Party” means, individually, any of the Settling Parties.

11           26. “State Action” means the derivative actions that were consolidated  
12 and styled as *In re MannKind Corp. Derivative Shareholder Litigation*, Lead Case  
13 No. BC454931 (Cal. Super. Ct. – Cnty. of L.A. filed Feb. 10, 2011).

14           27. “State Court” means the Superior Court of the State of California,  
15 County of Los Angeles.

16           28. “State Plaintiffs” means C. Kent Stephens, Sunshine Wire and Cable  
17 Defined Benefit Plan Trust, and Ira Gaines.

18           29. “State Plaintiffs’ Counsel” means Robbins Umeda LLP, the Grant  
19 Law Firm, PLLC, and Lasky & Rifkind, Ltd.

20           30. “Unknown Claims” means any Released Claim(s) which Plaintiffs or  
21 Defendants do not know of or suspect to exist in his, her, or its favor at the time of  
22 the release of the Released Persons. With respect to any and all Released Claims,  
23 the Settling Parties agree that upon the Effective Date, the Settling Parties  
24 expressly waive the provisions, rights and benefits conferred by or under  
25 California Civil Code section 1542, or any other law of the United States or any

26  
27  
28

1 state or territory of the United States, or principle of common law, which is similar,  
2 comparable, or equivalent to §1542, which provides:

3           A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS  
4           WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO  
5           EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING  
6           THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST  
7           HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT  
8           WITH THE DEBTOR.

8 The Settling Parties acknowledge that they may hereafter discover facts in addition  
9 to or different from those now known or believed to be true by them, with respect  
10 to the subject matter of the Released Claims, but it is the intention of the Settling  
11 Parties to completely, fully, finally, and forever compromise, settle, release,  
12 discharge, and extinguish any and all Released Claims, known or unknown,  
13 suspect or unsuspected, contingent or absolute, accrued or unaccrued, apparent or  
14 unapparent, which do now exist, or heretofore existed, or may hereafter exist, and  
15 without regard to the subsequent discovery of additional or different facts. The  
16 Settling Parties acknowledge that the foregoing waiver was separately bargained  
17 for and is a key element of the Stipulation of which this release is a part.

18 **II. THE ACTIONS**

19           In 2011, several MannKind shareholders filed derivative lawsuits in the  
20 Court and the State Court on behalf of MannKind and against the Individual  
21 Defendants for alleged violations of state law, including breach of fiduciary duty,  
22 insider selling and misappropriation of information, violations of Section 25402 of  
23 the California Corporations Code, waste of corporate assets, and unjust  
24 enrichment. Plaintiffs did not seek recovery for the direct benefit of any  
25 MannKind shareholder.

1           The Plaintiffs generally alleged, among other things, that the Individual  
2 Defendants: (i) failed to ensure that MannKind demonstrated the efficacy and  
3 safety of the AFREZZA-Dreamboat system using the methodologies required by  
4 the FDA; (ii) issued and failed to correct false and misleading statements to the  
5 effect that the FDA had approved MannKind’s flawed inhaler study methodology;  
6 and (iii) issued and failed to correct false and misleading statements concerning  
7 AFREZZA’s true prospects for FDA approval, all designed to conceal their  
8 mismanagement in jeopardizing the only product in MannKind’s drug  
9 development portfolio with near term commercial prospects. Defendants have  
10 denied and continue to deny each and all of the claims and contentions alleged by  
11 Plaintiffs in the Actions.

12           After extensive arm’s length negotiations, the Settling Parties reached an  
13 agreement to settle the Federal and State Action on the terms and conditions set  
14 forth in the Stipulation (the “Settlement”).

15 **III. PLAINTIFFS’ CLAIMS AND THE BENEFITS OF SETTLEMENT**

16           Plaintiffs believe the claims alleged in these Actions have merit.  
17 Nonetheless, Plaintiffs and Plaintiffs’ Counsel recognize and acknowledge the  
18 expense and length of time that would be required to prosecute the Actions through  
19 trial and possible appeals. Plaintiffs and Plaintiffs’ Counsel have also taken into  
20 account the uncertain outcome and the risk of any litigation, especially in complex  
21 cases such as the Actions, as well as the difficulties and delays inherent in such  
22 litigation. Plaintiffs and Plaintiffs’ Counsel are also mindful of the inherent  
23 problems of proof and possible defenses to the claims alleged in such actions.

24           Plaintiffs, through Plaintiffs’ Counsel, have conducted a thorough review  
25 and analysis of the relevant facts, allegations, defenses, and controlling legal  
26 principles, and believe that the settlement set forth in the Stipulation is fair,  
27  
28

1 reasonable, and adequate, confers substantial benefits upon, and is in the best  
2 interests of MannKind and its shareholders. Based upon Plaintiffs' Counsel's  
3 evaluation, Plaintiffs have determined that the settlement is in the best interests of  
4 MannKind and Current MannKind Shareholders and has agreed to settle the  
5 Actions upon the terms and subject to the conditions set forth in the Stipulation.

6 **IV. DEFENDANTS' DENIALS OF WRONGDOING AND LIABILITY**

7 Defendants have denied and continue to deny each and all of the claims and  
8 contentions alleged by Plaintiffs in the Actions. The Individual Defendants have  
9 expressly denied and continue to deny all charges of wrongdoing or liability  
10 against them arising out of any of the conduct, statements, acts, or omissions  
11 alleged, or that could have been alleged, in the Actions.

12 Nonetheless, Defendants have concluded that further litigation of the  
13 Actions would be protracted and expensive, and that it is desirable for the Actions  
14 to be fully and finally settled in the matter and upon the terms and conditions set  
15 forth in the Stipulation. Defendants have also taken into account the uncertainty  
16 and risks inherent in any litigation, especially in complex cases like the Actions.  
17 Defendants have, therefore, determined that it is desirable and beneficial that the  
18 Actions be settled in the manner and upon the terms and conditions set forth in the  
19 Stipulation.

20 Neither the Stipulation, nor any of its terms or provisions, nor entry of the  
21 Judgment, nor any document or exhibit referred or attached to the Stipulation, nor  
22 any action taken to carry out the Stipulation, is, may be construed as, or may be  
23 used as evidence of the validity of any of the Released Claims or an admission by  
24 or against the Individual Defendants of any fault, wrongdoing, or concession of  
25 liability whatsoever.

26  
27  
28

1 **V. THE SETTLEMENT HEARING**

2 The Settlement Hearing will be held before the Honorable Gary A. Feess on  
3 November 19, 2012 at 9:30 a.m. at the Edward R. Roybal Federal Building and  
4 United States Courthouse, 255 East Temple Street, Los Angeles, CA 90012, to  
5 determine whether: (i) the Settlement of the Actions upon the terms and subject to  
6 the conditions set forth in the Stipulation is fair, reasonable, and adequate and  
7 should be approved by the Court; (ii) the Actions should be dismissed with  
8 prejudice; and (iii) to approve the payment of Plaintiffs' attorneys' fees and  
9 expenses as set forth in the Stipulation. The Settlement Hearing may be continued  
10 by the Court at the Settlement Hearing, or at any adjourned session thereof without  
11 further notice.

12 **VI. TERMS OF THE SETTLEMENT**

13 The terms and conditions of the proposed Settlement are set forth in the  
14 Stipulation described above. The Stipulation has been filed with the Court and is  
15 also available for viewing on the websites of Robbins Umeda LLP at  
16 <http://www.robbinsumeda.com/notices.html>, Johnson & Weaver, LLP at  
17 <http://www.johnsonandweaver.com>, the Grant Law Firm PLLC at  
18 <http://Grantfirm.com>, and MannKind at <http://www.investors.mannkindcorp.com>.  
19 The following is only a summary of its terms.

20 The Parties have conducted arm's-length negotiations over an extended  
21 period of time and have reached an agreement in good-faith to settle the Actions.  
22 As consideration for the Settlement, MannKind has agreed to adopt and/or  
23 implement certain corporate governance reforms, as discussed below.

24 **Corporate Governance Reforms.** As a result of the filing, prosecution,  
25 and settlement of the Actions, MannKind has agreed to adopt the corporate  
26 governance reforms set forth in Exhibit A to the Stipulation within thirty (30) days  
27  
28

1 after the Judgment becomes Final, and to keep such reforms in force and effect for  
2 a period of no less than four years. MannKind and the Individual Defendants  
3 further acknowledge and agree that the corporate governance reforms would not  
4 have been implemented but for Plaintiffs' and Plaintiffs' Counsel's filing and  
5 prosecution of the Actions. MannKind and the Individual Defendants also  
6 acknowledge and agree that the corporate governance reforms are significant and  
7 extensive and confer substantial benefits upon MannKind and its shareholders by,  
8 among other things, strengthening MannKind's internal controls and helping to  
9 address the issues identified and alleged in the Actions.

## 10 **VII. DISMISSAL AND RELEASES**

11 In connection with the Court's approval of the Settlement, Plaintiffs will file  
12 a dismissal with prejudice of all claims asserted by Plaintiffs on behalf of  
13 MannKind and against the Individual Defendants in the Actions.

14 Upon the Effective Date, Plaintiffs, MannKind, and its shareholders, on  
15 behalf of themselves, their heirs, executors, administrators, insurers, predecessors,  
16 successors, and assigns, shall be deemed to have—and by operation of a final  
17 judgment in the Actions shall have—released, waived, discharged, and dismissed  
18 any and all Released Claims, and shall forever be barred and enjoined from  
19 instituting, commencing, or prosecuting any and all Released Claims against any  
20 Released Parties.

21 Further, upon the Effective Date, the Individual Defendants and each of the  
22 other Released Parties, on behalf of themselves, their heirs, executors,  
23 administrators, insurers, predecessors, successors, and assigns, shall be deemed to  
24 have—and by operation of a final judgment in the Actions shall have—released,  
25 waived, discharged, and dismissed any and all Defendants' settled claims, and  
26 shall forever be barred and enjoined from instituting, commencing, or prosecuting  
27  
28

1 any and all Defendants' settled claims, against Plaintiffs, Plaintiffs' Counsel, and  
2 MannKind.

3 **VIII. PLAINTIFFS' ATTORNEYS' FEES AND EXPENSES**

4 After negotiating the substantive terms of the settlement, the Parties  
5 discussed a fair and reasonable sum to be paid to Plaintiffs' Counsel for their  
6 attorneys' fees and expenses. In recognition of the substantial benefits conferred  
7 upon MannKind as a direct result of the prosecution and Settlement of the Actions,  
8 and as subject to Court approval, the Individual Defendants' insurers shall pay  
9 \$800,000 and MannKind shall deliver 225,000 shares of unrestricted MannKind  
10 common stock to Plaintiffs' Counsel for attorneys' fees and expenses. To date,  
11 Plaintiffs' Counsel have neither received any payment for their services in  
12 conducting the Actions, nor have counsel been reimbursed for their out-of-pocket  
13 expenses incurred. The Parties believe that the sum agreed to is within the range  
14 of attorneys' fees and expenses approved by courts under similar circumstances in  
15 litigation of this type. Neither the Individual Defendants nor MannKind's  
16 shareholders are personally liable for the payment of any award of attorneys' fees  
17 and expenses.

18 In addition, the Plaintiffs may apply to the Court for an incentive award of  
19 up to 1,000 shares of MannKind stock for each of the Plaintiffs, only to be paid  
20 upon Court approval, and to be paid from Plaintiffs' Counsel's stock amount in  
21 recognition of Plaintiffs' participation and effort in the prosecution of the Actions.  
22 Neither MannKind nor any of the Individual Defendants shall be liable for any  
23 portion of any incentive award.

24 **IX. THE RIGHT TO OBJECT AND/OR BE HEARD AT THE HEARING**

25 Any Current MannKind Shareholder may object and/or appear and show  
26 cause, if he, she, or it has any concern, why the Settlement should not be approved  
27  
28

1 as fair, reasonable, and adequate, or why the Judgment should not be entered  
2 thereon, or why the amount of attorneys' fees and reimbursement of expenses  
3 should not be approved. However, unless otherwise ordered by the Court, no  
4 Current MannKind Shareholder shall be heard or entitled to contest the approval of  
5 the terms and conditions of the Settlement, or, if approved, the Judgment to be  
6 entered thereon approving the same, or the amount of attorneys' fees and  
7 reimbursement of expenses to Plaintiffs' Counsel, unless that shareholder has, **by**  
8 **October 29, 2012:**

9 (1) filed with the Clerk of the Court a written objection to the settlement  
10 setting forth:

- 11 (a) the nature of the objection;
- 12 (b) proof of current ownership of MannKind common stock,  
13 including the number of shares of MannKind common stock  
14 and the date of purchase; and
- 15 (c) any documentation in support of such objection.

16 (2) If a Current MannKind Shareholder intends to appear and requests to  
17 be heard at the Settlement Hearing, such shareholder must have, in addition to the  
18 requirements of (1) above, filed with the Clerk of the Court:

- 19 (a) written notice of such shareholder's intention to appear;
- 20 (b) a statement that indicates the basis for such appearance; and
- 21 (c) the identities of any witnesses, if any, the shareholder intends to  
22 call at the Settlement Hearing and a statement as to the subject  
23 of their testimony.

24 If a Current MannKind Shareholder files a written objection and/or written  
25 notice of intent to appear, such shareholder ***must also simultaneously serve copies***  
26 ***of such notice, proof, statement, and documentation, together with copies of any***  
27  
28

1 *other papers or briefs such shareholder files with the Court (either by hand*  
2 *delivery or by first class mail) upon each of the following:*

3 ***The Court:***

4 Clerk of the Court  
5 U.S. District Court  
6 Central District of California  
7 255 East Temple Street  
8 Los Angeles, CA 90012

9 ***Counsel for Plaintiffs:***

10 ROBBINS UMEDA LLP  
11 Attn: Lauren G. Levi  
12 600 B Street, Suite 1900  
13 San Diego, CA 92101  
14 Telephone: (619) 525-3990

JOHNSON & WEAVER, LLP  
Attn: Frank J. Johnson  
110 West "A" Street, Suite 750  
San Diego, CA 92101  
Telephone: (619) 230-0063  
Facsimile: (619) 255-1856

14 THE GRANT LAW FIRM, PLLC  
15 Attn: Lynda J. Grant  
16 521 Fifth Avenue, 17th Floor  
17 New York, NY 10175  
18 Telephone: (212)292-4441  
19 Facsimile: (212) 292-4442

20 ***Counsel for Defendants:***

20 COOLEY LLP  
21 Attn: Koji Fukumura  
22 4401 Eastgate Mall  
23 San Diego, CA 92121  
24 Telephone: (858) 550-6000  
25 Facsimile: (858) 550-6420

25 Unless otherwise ordered by the Court, any Current MannKind Shareholder  
26 who does not make his, her, or its objection in the manner provided herein shall be  
27  
28

1 deemed to have waived such objection and shall forever be barred and foreclosed  
2 from making any objection to the fairness, reasonableness, or adequacy of the  
3 Settlement, to Plaintiffs' Counsel's award of attorneys' fees and expenses, or to  
4 otherwise be heard, and shall otherwise be bound by the Judgment to be entered  
5 and the releases to be given.

6 **X. CONDITIONS FOR SETTLEMENT**

7 The Settlement is conditioned upon the occurrence of certain events  
8 described in the Stipulation, which requires, among other things: (a) approval of  
9 the Settlement by MannKind's Board of Directors, which Defendants' Counsel  
10 represent has already been accomplished; (b) approval of the Settlement by the  
11 Court following notice to MannKind shareholders, as set forth in paragraph 3.2 of  
12 the Stipulation, and a hearing as required by Rule 23.1; (c) entry of the Judgment,  
13 in all material respects in the form set forth as Exhibit D annexed to the  
14 Stipulation, approving the Settlement and dismissing with prejudice the Federal  
15 Action, without awarding costs to any party, except as provided herein; (d) the  
16 payment of the Stock Amount and Fee and Expense Amount in accordance with  
17 paragraph 4 of the Stipulation; and (e) the passing of the date upon which the  
18 Judgment becomes Final. If, for any reason, any one of the conditions described in  
19 the Stipulation is not met and the entry of the Judgment does not occur, the  
20 Stipulation might be terminated and, if terminated, will become null and void; and  
21 the Parties to the Stipulation will be restored to their respective positions as of July  
22 2, 2012.

23 **XI. EXAMINATION OF PAPERS AND INQUIRIES**

24 There is additional information concerning the Settlement available in the  
25 Stipulation, which may be viewed on the website of Robbins Umeda LLP at  
26 <http://www.robbinsumeda.com/notices.html>, Johnson & Weaver, LLP at  
27  
28

1 <http://www.johnsonandweaver.com>, the Grant Law Firm PLLC at  
2 <http://Grantfirm.com>, and MannKind at <http://www.investors.mannkindcorp.com>.  
3 You may also inspect the Stipulation during business hours at the office of the  
4 Clerk of the Court, U.S. District Court, Central District of California, 255 East  
5 Temple Street, Los Angeles, CA 90012. Or you can call Robbins Umeda LLP,  
6 600 B Street, Suite 1900, San Diego, California 92101, Telephone: (619) 525-  
7 3990, for additional information concerning the settlement.

8 **PLEASE DO NOT TELEPHONE THE COURT OR**  
9 **MANKIND REGARDING THIS NOTICE.**

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

768466